HIT Consultant November 13, 2024
Life science companies, particularly those heavily invested in research and development, often face critical funding decisions. Should they pursue an initial public offering (IPO) to fuel their growth, or is a strategic buyout from a larger company a more suitable path?
In this exclusive interview, Taylor Wirth, a partner at Barnes & Thornburg, offers his insights on evaluating market conditions, assessing company readiness, and weighing the pros and cons of each funding option. He also highlights the importance of considering factors such as drug development pipelines, FDA approval processes, financial health, and potential litigation when making this crucial decision.
How can life science companies assess the market receptiveness to their potential IPO, especially considering the biotech/pharma sector?
Taylor Wirth, Partner...
Today's Sponsors
Today's Sponsor